search
Back to results

Detection of COVID-19 Subjects Using DiaNose Exhalation Test

Primary Purpose

COVID-19

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
DiaNose
Sponsored by
Nanose Medical Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for COVID-19

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Corona Suspected Subjects

  1. Subject ≥18 years of age
  2. Verified exposure to COVID-19 virus
  3. Physical or Radiological evidence of Pneumonia or other Upper Respiratory Tract Infection
  4. Subject with at least one of the following symptoms: Fever >37.80c P.O with no alternative source for infection / Cough / Nasal discharge or congestion / Shortness of breath (subjective or objective) with no alternative explanation / Sore throat / Loss of taste and smell / Combination of headache, general malaise, fatigue or other nonspecific URTI (upper respiratory tract infection) symptoms / GI symptoms (not as a signal symptom)
  5. Subject has undergone PCR test or is about to undergo the test immediately
  6. Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed
  7. Subject is able and willing to adhere to the required testing

Exclusion Criteria:

  1. Subject with HIV
  2. Subject addicted to alcohol and/or drugs
  3. Subject with active gingivitis
  4. Subject with COPD (Chronic Obstructive Pulmonary Disease)
  5. During the last hour before examination the subject ate including chewing gum / smoked/ Drank (any drink beside water)/performed excessive physical activity
  6. Subject is pregnant (confirmed by subject declaration)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    DiaNose procedure

    Arm Description

    all subjects will be required to undergo the DiaNose exhalation test.

    Outcomes

    Primary Outcome Measures

    collecting and analyzing of DiaNose sensors signals from potential VOC markers in the breath samples of all subjects to build and validate a predictive algorithmic model for diagnosing COVID 19.
    Sensing Features (SFs) extracted from each of the sensors are used for statistical analysis by artificially intelligent/pattern recognition algorithm.

    Secondary Outcome Measures

    Full Information

    First Posted
    June 16, 2020
    Last Updated
    July 16, 2020
    Sponsor
    Nanose Medical Ltd.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04476927
    Brief Title
    Detection of COVID-19 Subjects Using DiaNose Exhalation Test
    Official Title
    Collecting and Evaluating Data of Potential Volatile Biomarkers in the Exhaled Air of Subjects With and Without COVID-19 by DiaNose
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2020
    Overall Recruitment Status
    Unknown status
    Study Start Date
    August 1, 2020 (Anticipated)
    Primary Completion Date
    May 30, 2021 (Anticipated)
    Study Completion Date
    June 30, 2021 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Nanose Medical Ltd.

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Device Product Not Approved or Cleared by U.S. FDA
    Yes
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The study aim is to collect and analyze data of potential Volatile Organic Compounds (VOCs) that could be used for discriminating between patients with and without COVID-19 or with high-risk for COVID-19 by DiaNose breath test. up to 300 subjects will be enrolled to the study ( 200 COVID-19 suspected and 100 healthy volunteers in two clinical sites (1 in Israel and 1 in US). DiaNose system is an electronic nose device that can "smell" diseases in the exhaled breath of patients in real time. This approach is non-invasive, simple and save. The DiaNose prototype system consists the following elements: A Soft Tube connected to a Sensors Chamber - The soft tube is made of medical grade silicon. The subject blows air into the tube for a few seconds and the exhaled air is directed through the sensors chamber. This unit is for single use. • Sensors Reading Unit- a multi used unit for sensors signals measurement. The Sensor Reading Unit is connected to a Laptop that is used to activate and save the test measurements.
    Detailed Description
    This study is a prospective, multi-center research clinical study. The aim of this study is to collect and analyze data of potential Volatile Organic Compounds (VOCs) that could be used for discriminating between patients with and without COVID-19 or with high-risk for COVID-19 by DiaNose. The VOC profile of exhaled breath from subjects with COVID-19 infected suspected; and healthy volunteers, will be collected and analyzed to build and validate a predictive algorithmic model for diagnosing COVID 19. Subjects which are COVID-19 infected suspected (Group 1); and healthy volunteers (Group 2), will be the study population. The study will encompass a total of up to 300 patients. The COVID-19 infected suspected study group will be divided for the data analyzing and algorithm building into the following sub-groups (up to 200 subjects): Sub-Group A: Clinical symptomatic patients with positive Covid-19 test (positive PCR); Sub-Group B: Asymptomatic patients with positive Covid-19 test (positive PCR) Sub-Group C: Clinical symptomatic patients with negative Covid-19 test (negative PCR) Additional sub-groups may be added according to clinical symptoms. Up to 100 will be enrolled to the Healthy volunteers' study group. Subjects who meet general entry criteria will be asked to sign the study-specific Informed Consent Form the patient will be required not to eat/ smoke/ chewing gum or drink beverage other than water for one hour prior to the DiaNose exhalation test. The patient will be asked to blow air into a disposable tube for a few seconds. Subject may be re-enrolled in case of need to perform additional PCR test and/or breath test with DiaNose according to standard of care or due to the study needs. It is anticipated that it will require approximately 12 months to complete active enrollment.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    COVID-19

    7. Study Design

    Primary Purpose
    Other
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Model Description
    Total of 300 subjects - 200 suspected to COVID-19 and 100 healthy volunteers. all subjects will be undergo the DiaNose test. For data analysis and algorithm building, subjects will be divided into one of the following study groups: Group 1: Covid-19 infected suspected (up to 300 subjects) Sub-Group A: Clinical symptomatic patients with positive Covid-19 test (positive PCR); Sub-Group B: Asymptomatic patients with positive Covid-19 test (positive PCR) Sub-Group C: Clinical symptomatic patients with negative Covid-19 test (negative PCR) Additional sub-groups may be added according to clinical symptoms. Group 2: Healthy volunteers (up to 100 subjects)
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    300 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    DiaNose procedure
    Arm Type
    Experimental
    Arm Description
    all subjects will be required to undergo the DiaNose exhalation test.
    Intervention Type
    Device
    Intervention Name(s)
    DiaNose
    Intervention Description
    DiaNose system is an electronic nose device that can "smell" diseases in the exhaled breath of patients in real time. The recognition of Volatile Organic Compounds (VOCs) in breath samples approach is non-invasive and for safe diagnosis of diseases. The DiaNose prototype system consists the following elements: A Soft Tube connected to a Sensors Chamber - The soft tube is made of medical grade silicon. The subject blows air into the tube for a few seconds and the exhaled air is directed through the sensors chamber. This unit is for single use. Sensors Reading Unit- a multi used unit for sensors signals measurement. The Sensor Reading Unit is connected to a Laptop either via a Data Acquisition Instrument - Commercial unit for resistance measurements (https://www.tek.com/keithley-switching-and-data-acquisition-systems/keithley-daq6510) (option A ) or directly by a USB cable (option B). Laptop - Laptop is used to activate and save the test measurements.
    Primary Outcome Measure Information:
    Title
    collecting and analyzing of DiaNose sensors signals from potential VOC markers in the breath samples of all subjects to build and validate a predictive algorithmic model for diagnosing COVID 19.
    Description
    Sensing Features (SFs) extracted from each of the sensors are used for statistical analysis by artificially intelligent/pattern recognition algorithm.
    Time Frame
    1 hour

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Corona Suspected Subjects Subject ≥18 years of age Verified exposure to COVID-19 virus Physical or Radiological evidence of Pneumonia or other Upper Respiratory Tract Infection Subject with at least one of the following symptoms: Fever >37.80c P.O with no alternative source for infection / Cough / Nasal discharge or congestion / Shortness of breath (subjective or objective) with no alternative explanation / Sore throat / Loss of taste and smell / Combination of headache, general malaise, fatigue or other nonspecific URTI (upper respiratory tract infection) symptoms / GI symptoms (not as a signal symptom) Subject has undergone PCR test or is about to undergo the test immediately Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed Subject is able and willing to adhere to the required testing Exclusion Criteria: Subject with HIV Subject addicted to alcohol and/or drugs Subject with active gingivitis Subject with COPD (Chronic Obstructive Pulmonary Disease) During the last hour before examination the subject ate including chewing gum / smoked/ Drank (any drink beside water)/performed excessive physical activity Subject is pregnant (confirmed by subject declaration)
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Ravit Peled
    Phone
    +972 526145354
    Email
    ravitp@nanosemed.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Ravit Peled
    Organizational Affiliation
    Nanose Medical
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    Detection of COVID-19 Subjects Using DiaNose Exhalation Test

    We'll reach out to this number within 24 hrs